KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ionis Pharmaceuticals (IONS) Invested Capital (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Invested Capital for 18 consecutive years, with $923.9 million as the latest value for Q1 2026.

  • For Q1 2026, Invested Capital rose 94.21% year-over-year to $923.9 million; the TTM value through Mar 2026 reached $923.9 million, up 94.21%, while the annual FY2025 figure was $921.0 million, 56.55% up from the prior year.
  • Invested Capital hit $923.9 million in Q1 2026 for Ionis Pharmaceuticals, roughly flat from $921.0 million in the prior quarter.
  • Across five years, Invested Capital topped out at $1.3 billion in Q2 2025 and bottomed at $308.1 million in Q2 2024.
  • Average Invested Capital over 5 years is $644.3 million, with a median of $588.4 million recorded in 2024.
  • Year-over-year, Invested Capital tumbled 47.36% in 2023 and then soared 309.53% in 2025.
  • Ionis Pharmaceuticals' Invested Capital stood at $572.9 million in 2022, then decreased by 24.76% to $431.0 million in 2023, then surged by 36.5% to $588.4 million in 2024, then skyrocketed by 56.55% to $921.0 million in 2025, then grew by 0.31% to $923.9 million in 2026.
  • According to Business Quant data, Invested Capital over the past three periods came in at $923.9 million, $921.0 million, and $1.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.